Abstract The advent of Anti- VEGFs like Lucentis (Ranibizumab). Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD). Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). It is a matter of great concern that the US patents for Ranibizumab and Aflibercept expired in ... https://pipingrockers.shop/product-category/luteolin/